{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:12:56Z","timestamp":1793722376917,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009131","name":"Direktion f\u00fcr Entwicklung und Zusammenarbeit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007729","name":"Ministerie van Buitenlandse Zaken","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijpddr.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T22:46:49Z","timestamp":1551134809000},"page":"129-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis"],"prefix":"10.1016","volume":"11","author":[{"given":"Katrien","family":"Van Bocxlaer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Caridha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Leed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert-Jan","family":"Wijnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Braillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Mowbray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Robert","family":"Ioset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon L.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijpddr.2019.02.002_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"96","author":"Aronson","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"12","key":"10.1016\/j.ijpddr.2019.02.002_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189906","article-title":"\"The mosquitoes that destroy your face\". Social impact of Cutaneous Leishmaniasis in South-eastern Morocco, A qualitative study","volume":"12","author":"Bennis","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ijpddr.2019.02.002_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0625.2000.009003165.x","article-title":"The 500 Dalton rule for the skin penetration of chemical compounds and drugs","volume":"9","author":"Bos","year":"2000","journal-title":"Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.ijpddr.2019.02.002_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02048-16","article-title":"Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis","volume":"61","author":"Caridha","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.02.002_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02048-16","article-title":"Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost Effective Drug Screen as Part of a Tiered In vivo Screening Paradigm for Development of Drugs to Treat Cutaneous Leishmaniasis","author":"Caridha","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ijpddr.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s11095-010-0292-6","article-title":"The rule of five for non-oral routes of drug delivery: ophthalmic, inhalation and transdermal","volume":"28","author":"Choy","year":"2011","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.ijpddr.2019.02.002_bib7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy-challenges and opportunities","volume":"17","author":"Croft","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"issue":"6","key":"10.1016\/j.ijpddr.2019.02.002_bib8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1042\/ETLS20170103","article-title":"Antileishmanial and antitrypanosomal drug identification","volume":"1","author":"Croft","year":"2017","journal-title":"Emerg. Topics Life Sci."},{"issue":"10","key":"10.1016\/j.ijpddr.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2014.921158","article-title":"Tavaborole for the treatment of onychomycosis","volume":"15","author":"Elewski","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.ijpddr.2019.02.002_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0001-706X(01)00197-8","article-title":"Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B","volume":"81","author":"Escobar","year":"2002","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2019.02.002_bib11","article-title":"Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis","author":"Fairlamb","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.ijpddr.2019.02.002_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/jidsymp.1998.27","article-title":"The selection and design of topical and transdermal agents: a review","volume":"3","author":"Hadgraft","year":"1998","journal-title":"J. Invest. Dermatol. Symp. Proc."},{"issue":"6","key":"10.1016\/j.ijpddr.2019.02.002_bib13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/QCO.0b013e32834c630e","article-title":"Boron-based drugs as antiprotozoals","volume":"24","author":"Jacobs","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ijpddr.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4155\/fmc.11.80","article-title":"Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis","volume":"3","author":"Jacobs","year":"2011","journal-title":"Future Med. Chem."},{"issue":"10","key":"10.1016\/j.ijpddr.2019.02.002_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0000259","article-title":"Marring leishmaniasis: the stigmatization and the impact of cutaneous leishmaniasis in Pakistan and Afghanistan","volume":"2","author":"Kassi","year":"2008","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"2","key":"10.1016\/j.ijpddr.2019.02.002_bib16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4269\/ajtmh.15-0448","article-title":"Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes","volume":"94","author":"Khraiwesh","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.ijpddr.2019.02.002_bib17","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1371\/journal.pntd.0000034","article-title":"Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL\/6 Model","volume":"1","author":"Lecoeur","year":"2007","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2019.02.002_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpddr.2019.02.002_bib19","series-title":"Drug Discovery for Leishmaniasis","first-page":"24","article-title":"Anti-leishmanial drug discovery: past, present and future perspectives","author":"Mowbray","year":"2018"},{"issue":"24","key":"10.1016\/j.ijpddr.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2014.09.006","article-title":"In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis","volume":"65","author":"Mukkavilli","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ijpddr.2019.02.002_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1461-5347(00)00295-9","article-title":"Transdermal drug delivery: overcoming the skin's barrier function","volume":"3","author":"Naik","year":"2000","journal-title":"Pharmaceut. Sci. Technol. Today"},{"issue":"10","key":"10.1016\/j.ijpddr.2019.02.002_bib23","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.00498-10","article-title":"Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis","volume":"54","author":"Nare","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.02.002_bib25","first-page":"538629","article-title":"Mucocutaneous leishmaniasis: knowledge, attitudes, and practices among paraguayan communities, patients, and health professionals","author":"Ruoti","year":"2013","journal-title":"J. Trop. Med."},{"issue":"6","key":"10.1016\/j.ijpddr.2019.02.002_bib26","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ijpddr.2019.02.002_bib27","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/acs.jmedchem.7b00034","article-title":"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis","volume":"60","author":"Thompson","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijpddr.2019.02.002_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02419-17","article-title":"Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles","volume":"62","author":"Van Bocxlaer","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ijpddr.2019.02.002_bib29","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/jac\/dkw012","article-title":"Drug permeation and barrier damage in Leishmania-infected mouse skin","volume":"71","author":"Van Bocxlaer","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.ijpddr.2019.02.002_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpddr.2018.01.006","article-title":"In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series","volume":"8","author":"Van den Kerkhof","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"issue":"2","key":"10.1016\/j.ijpddr.2019.02.002_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpddr.2018.04.001","article-title":"Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome((R)) and AmBisome((R)) in murine cutaneous leishmaniasis","volume":"8","author":"Wijnant","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"issue":"3","key":"10.1016\/j.ijpddr.2019.02.002_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02009-17","article-title":"Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis","volume":"62","author":"Wijnant","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.ijpddr.2019.02.002_bib33","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1021\/acs.jmedchem.7b00621","article-title":"Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate","volume":"60","author":"Zhang","year":"2017","journal-title":"J. Med. Chem."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320718301854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320718301854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:49:13Z","timestamp":1761922153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320718301854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"alternative-id":["S2211320718301854"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.02.002","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}